{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:53:31Z","timestamp":1768625611779,"version":"3.49.0"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1888,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1002\/hep.23637","type":"journal-article","created":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T20:25:53Z","timestamp":1267475153000},"page":"349-359","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":80,"title":["American Association for the Study of Liver Diseases Endpoints Conference: Design and Endpoints for Clinical Trials in Primary Biliary Cirrhosis"],"prefix":"10.1097","volume":"52","author":[{"given":"Marina G.","family":"Silveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Brunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Heathcote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-36-20250312","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1016\/S0140-6736(03)13808-1","article-title":"Primary biliary cirrhosis.","volume":"362","author":"Talwalkar","year":"2003","journal-title":"Lancet"},{"key":"R2-36-20250312","doi-asserted-by":"crossref","first-page":"12611273","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis.","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-36-20250312","doi-asserted-by":"crossref","first-page":"8995","DOI":"10.1053\/cgh.2003.50014","article-title":"When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?","volume":"1","author":"Zein","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-36-20250312","doi-asserted-by":"crossref","first-page":"830836","DOI":"10.1093\/ije\/26.4.830","article-title":"Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England.","volume":"26","author":"Metcalf","year":"1997","journal-title":"Int J Epidemiol"},{"key":"R5-36-20250312","doi-asserted-by":"crossref","first-page":"927930","DOI":"10.1136\/gut.36.6.927","article-title":"Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group.","volume":"36","author":"Watson","year":"1995","journal-title":"Gut"},{"key":"R6-36-20250312","doi-asserted-by":"crossref","first-page":"265280","DOI":"10.1055\/s-2005-916319","article-title":"Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology.","volume":"25","author":"Selmi","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R7-36-20250312","doi-asserted-by":"crossref","first-page":"390394","DOI":"10.1002\/hep.510300213","article-title":"Primary biliary cirrhosis once rare, now common in the United Kingdom?","volume":"30","author":"James","year":"1999","journal-title":"Hepatology"},{"key":"R8-36-20250312","doi-asserted-by":"crossref","first-page":"458464","DOI":"10.1002\/hep.1840110317","article-title":"Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden.","volume":"11","author":"Danielsson","year":"1990","journal-title":"Hepatology"},{"key":"R9-36-20250312","doi-asserted-by":"crossref","first-page":"16311636","DOI":"10.1053\/gast.2000.20197","article-title":"3rd, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community.","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"key":"R10-36-20250312","doi-asserted-by":"crossref","first-page":"179183","DOI":"10.1016\/S0025-6196(11)63652-5","article-title":"Ludwig Symposium on biliary disorderspart II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis.","volume":"73","author":"Scheuer","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"R11-36-20250312","doi-asserted-by":"crossref","first-page":"13991402","DOI":"10.1016\/S0140-6736(96)04410-8","article-title":"Natural history of early primary biliary cirrhosis.","volume":"348","author":"Metcalf","year":"1996","journal-title":"Lancet"},{"key":"R12-36-20250312","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis.","volume":"94","author":"Springer","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R13-36-20250312","doi-asserted-by":"crossref","first-page":"10441051","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: followup for up to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R14-36-20250312","doi-asserted-by":"crossref","first-page":"884890","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"R15-36-20250312","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"R16-36-20250312","doi-asserted-by":"crossref","first-page":"871877","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and longterm prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"R17-36-20250312","doi-asserted-by":"crossref","first-page":"715720","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent longterm survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"R18-36-20250312","doi-asserted-by":"crossref","first-page":"12811287","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"R19-36-20250312","doi-asserted-by":"crossref","first-page":"291308","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R20-36-20250312","doi-asserted-by":"crossref","first-page":"243248","DOI":"10.1053\/jhep.2001.26514","article-title":"Detection of antimitochondrial autoantibodies in immunofluorescent AMAnegative patients with primary biliary cirrhosis using recombinant autoantigens.","volume":"34","author":"Miyakawa","year":"2001","journal-title":"Hepatology"},{"key":"R21-36-20250312","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1097\/01.MP.0000042420.21088.C7","article-title":"Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.","volume":"16","author":"Brunt","year":"2003","journal-title":"Mod Pathol"},{"key":"R22-36-20250312","doi-asserted-by":"crossref","first-page":"929938","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R23-36-20250312","doi-asserted-by":"crossref","first-page":"12441250","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: longterm outcomes.","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R24-36-20250312","doi-asserted-by":"crossref","first-page":"652658","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodioltreated patients.","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"R25-36-20250312","doi-asserted-by":"crossref","first-page":"276281","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in noncirrhotic primary biliary cirrhosis: the premature ductopenic variant.","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"key":"R26-36-20250312","doi-asserted-by":"crossref","first-page":"17771790","DOI":"10.1016\/0016-5085(85)90001-0","article-title":"Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients.","volume":"88","author":"Portmann","year":"1985","journal-title":"Gastroenterology"},{"key":"R27-36-20250312","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/hep.510230108","article-title":"3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis.","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"key":"R28-36-20250312","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making.","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"R29-36-20250312","doi-asserted-by":"crossref","first-page":"15521560","DOI":"10.1053\/j.gastro.2008.07.019","article-title":"Portal hypertension and primary biliary cirrhosis: effect of longterm ursodeoxycholic acid treatment.","volume":"135","author":"Huet","year":"2008","journal-title":"Gastroenterology"},{"key":"R30-36-20250312","first-page":"11231130","article-title":"Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis.","volume":"26","author":"Zuchner","year":"1997","journal-title":"Hepatology"},{"key":"R31-36-20250312","doi-asserted-by":"crossref","first-page":"118127","DOI":"10.1002\/hep.21472","article-title":"Antigp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis.","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"R32-36-20250312","doi-asserted-by":"crossref","first-page":"15491557","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"key":"R33-36-20250312","doi-asserted-by":"crossref","first-page":"10841091","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial.","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"key":"R34-36-20250312","doi-asserted-by":"crossref","first-page":"119126","DOI":"10.3109\/00365529009107932","article-title":"Factors of prognostic importance in primary biliary cirrhosis.","volume":"25","author":"Rydning","year":"1990","journal-title":"Scand J Gastroenterol"},{"key":"R35-36-20250312","doi-asserted-by":"crossref","first-page":"17091713","DOI":"10.1056\/NEJM198906293202602","article-title":"Efficiency of liver transplantation in patients with primary biliary cirrhosis.","volume":"320","author":"Markus","year":"1989","journal-title":"N Engl J Med"},{"key":"R36-36-20250312","doi-asserted-by":"crossref","first-page":"137140","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary cirrhosis.","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"key":"R37-36-20250312","doi-asserted-by":"crossref","first-page":"865869","DOI":"10.1002\/hep.510300415","article-title":"Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?","volume":"30","author":"Krzeski","year":"1999","journal-title":"Hepatology"},{"key":"R38-36-20250312","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/hep.510290140","article-title":"Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.","volume":"29","author":"Bonnand","year":"1999","journal-title":"Hepatology"},{"key":"R39-36-20250312","doi-asserted-by":"crossref","first-page":"11841193","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"key":"R40-36-20250312","doi-asserted-by":"crossref","first-page":"26472650","DOI":"10.1111\/j.1572-0241.2002.06043.x","article-title":"Results of longterm ursodiol treatment for patients with primary biliary cirrhosis.","volume":"97","author":"Jorgensen","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R41-36-20250312","doi-asserted-by":"crossref","first-page":"20442050","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic Acidtreated patients with primary biliary cirrhosis. Results of a 10yr cohort study involving 297 patients.","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R42-36-20250312","doi-asserted-by":"crossref","first-page":"464470","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with endstage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R43-36-20250312","doi-asserted-by":"crossref","first-page":"15521559","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival.","volume":"96","author":"Gores","year":"1989","journal-title":"Gastroenterology"},{"key":"R44-36-20250312","doi-asserted-by":"crossref","first-page":"11371140","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis.","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"R45-36-20250312","first-page":"759766","article-title":"A randomized, doubleblind, placebocontrolled trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"R46-36-20250312","doi-asserted-by":"crossref","first-page":"774780","DOI":"10.1007\/BF02779195","article-title":"A multicenter doubleblind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis.","volume":"25","author":"Oka","year":"1990","journal-title":"Gastroenterol Jpn"},{"key":"R47-36-20250312","first-page":"922938","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.","volume":"46","author":"GarciaTsao","year":"2007","journal-title":"Hepatology"},{"key":"R48-36-20250312","doi-asserted-by":"crossref","first-page":"122127","DOI":"10.2214\/AJR.07.3504","article-title":"Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension.","volume":"193","author":"Talwalkar","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"R49-36-20250312","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis.","volume":"308","author":"Roll","year":"1983","journal-title":"N Engl J Med"},{"key":"R50-36-20250312","doi-asserted-by":"crossref","first-page":"187193","DOI":"10.1111\/j.1478-3231.2004.0918.x","article-title":"Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCAtreated patients with primary biliary cirrhosis.","volume":"24","author":"Corpechot","year":"2004","journal-title":"Liver Int"},{"key":"R51-36-20250312","doi-asserted-by":"crossref","first-page":"747752","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a threeyear randomized trial.","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"R52-36-20250312","doi-asserted-by":"crossref","first-page":"598607","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases.","volume":"47","author":"Goodman","year":"2007","journal-title":"J Hepatol"},{"key":"R53-36-20250312","doi-asserted-by":"crossref","first-page":"13231330","DOI":"10.1053\/gast.2002.35953","article-title":"Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.","volume":"123","author":"Canbay","year":"2002","journal-title":"Gastroenterology"},{"key":"R54-36-20250312","doi-asserted-by":"crossref","first-page":"103112","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"R55-36-20250312","first-page":"12571260","article-title":"Primary biliary cirrhosis.","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc R Soc Med"},{"key":"R56-36-20250312","doi-asserted-by":"crossref","first-page":"707713","DOI":"10.1016\/S0168-8278(05)80139-4","article-title":"Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years.","volume":"20","author":"Mahl","year":"1994","journal-title":"J Hepatol"},{"key":"R57-36-20250312","doi-asserted-by":"crossref","first-page":"552553","DOI":"10.1038\/ncpgasthep0360","article-title":"Patients and patience: the pitfalls of primary biliary cirrhosis trials.","volume":"2","author":"Mayo","year":"2005","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"R58-36-20250312","doi-asserted-by":"crossref","first-page":"13191324","DOI":"10.1016\/0016-5085(92)90771-P","article-title":"Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis.","volume":"102","author":"Colina","year":"1992","journal-title":"Gastroenterology"},{"key":"R59-36-20250312","doi-asserted-by":"crossref","first-page":"11961199","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"R60-36-20250312","doi-asserted-by":"crossref","first-page":"11181124","DOI":"10.1002\/hep.21151","article-title":"Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.","volume":"43","author":"Corpechot","year":"2006","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"R62-36-20250312","first-page":"S79S83","article-title":"Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.","volume":"18","author":"Fisk","year":"1994","journal-title":"Clin Infect Dis"},{"key":"R63-36-20250312","first-page":"705710","article-title":"Fatigue in primary biliary cirrhosis.","volume":"43","author":"CauchDudek","year":"1998","journal-title":"Gut"},{"key":"R64-36-20250312","doi-asserted-by":"crossref","first-page":"368373","DOI":"10.1016\/S0168-8278(00)80385-2","article-title":"Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use.","volume":"32","author":"Prince","year":"2000","journal-title":"J Hepatol"},{"key":"R65-36-20250312","doi-asserted-by":"crossref","first-page":"760767","DOI":"10.1111\/j.1572-0241.2000.01857.x","article-title":"Impact of fatigue on the quality of life of patients with primary biliary cirrhosis.","volume":"95","author":"Huet","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R66-36-20250312","doi-asserted-by":"crossref","first-page":"12351241","DOI":"10.1053\/gast.2002.32993","article-title":"The true impact of fatigue in primary biliary cirrhosis: a population study.","volume":"122","author":"Goldblatt","year":"2002","journal-title":"Gastroenterology"},{"key":"R67-36-20250312","doi-asserted-by":"crossref","first-page":"16221629","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC40, a disease specific health related quality of life measure for primary biliary cirrhosis.","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"key":"R68-36-20250312","doi-asserted-by":"crossref","first-page":"776783","DOI":"10.1016\/j.jhep.2005.12.012","article-title":"Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure.","volume":"44","author":"Newton","year":"2006","journal-title":"J Hepatol"},{"key":"R69-36-20250312","doi-asserted-by":"crossref","first-page":"471476","DOI":"10.1111\/j.1365-2036.2006.03223.x","article-title":"An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis.","volume":"25","author":"Jones","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R70-36-20250312","first-page":"S76","article-title":"New scale to measure pruritus: the 5D.","volume":"128","author":"Elman","year":"2008","journal-title":"Journal of Investigative Dermatology"},{"key":"R71-36-20250312","first-page":"400403","article-title":"Application of piezo film technology for the quantitative assessment of pruritus.","volume":"25","author":"Talbot","year":"1991","journal-title":"Biomed Instrum Technol"},{"key":"R72-36-20250312","first-page":"12891291","article-title":"Testosterone therapy for the pruritus of obstructive jaundice.","volume":"2","author":"LloydThomas","year":"1952","journal-title":"Br Med J"},{"key":"R73-36-20250312","first-page":"550A","article-title":"Rituximab for primary biliary cirrhosis refractory to ursodeoxycholic acid Abstract.","volume":"46","author":"Myers","year":"2007","journal-title":"Hepatology"},{"key":"R74-36-20250312","doi-asserted-by":"crossref","first-page":"662669","DOI":"10.1002\/hep.22402","article-title":"Statins in liver disease: a molehill, an iceberg, or neither?","volume":"48","author":"Argo","year":"2008","journal-title":"Hepatology"},{"key":"R75-36-20250312","doi-asserted-by":"crossref","first-page":"19881993","DOI":"10.1007\/s10620-007-0003-2","article-title":"Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis.","volume":"53","author":"Stanca","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R76-36-20250312","doi-asserted-by":"crossref","first-page":"326327","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R77-36-20250312","doi-asserted-by":"crossref","first-page":"29902992","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R78-36-20250312","doi-asserted-by":"crossref","first-page":"573578","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"R79-36-20250312","doi-asserted-by":"crossref","first-page":"25442555","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med"},{"key":"R80-36-20250312","doi-asserted-by":"crossref","first-page":"496497","DOI":"10.1038\/ncpgasthep1200","article-title":"What is the potential role of antifibrotic agents for the treatment of liver disease?","volume":"5","author":"Schnabl","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23637","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201007000-00036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:05:48Z","timestamp":1741777548000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201007000-00036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23637","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}